A previous preclinical investigation indicated that galunisertib in association with anti-PD-L1 treatment had remarkably superior tumor abrogation and anti-tumor efficacy than either galunisertib or anti-PD-L1 monotherapy, suggesting that galunisertib induces increased anti-tumor T cell immunity (42). The gene discussed is CD274; the disease is neoplasm.